MX386402B - Tratamiento con trastuzumab vc-seco-duba de pacientes de cáncer refractarios a trastuzumab emtansina. - Google Patents

Tratamiento con trastuzumab vc-seco-duba de pacientes de cáncer refractarios a trastuzumab emtansina.

Info

Publication number
MX386402B
MX386402B MX2018003459A MX2018003459A MX386402B MX 386402 B MX386402 B MX 386402B MX 2018003459 A MX2018003459 A MX 2018003459A MX 2018003459 A MX2018003459 A MX 2018003459A MX 386402 B MX386402 B MX 386402B
Authority
MX
Mexico
Prior art keywords
trastuzumab
cancer patients
duba
seco
treatment
Prior art date
Application number
MX2018003459A
Other languages
English (en)
Other versions
MX2018003459A (es
Inventor
Gerrit Voortman
Norbert Peter Koper
Original Assignee
Byondis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis Bv filed Critical Byondis Bv
Publication of MX2018003459A publication Critical patent/MX2018003459A/es
Publication of MX386402B publication Critical patent/MX386402B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con trastuzumab vc-seco-DUBA (SYD985) del conjugado anticuerpo-fármaco (ADC) que contiene duocarmicina para usarse en el tratamiento pacientes de cáncer HER2 IHC 3+ o HER2 IHC 2+/FISH positivo refractarios a trastuzumab emtansina (T-DM1), particularmente de pacientes de cáncer de mama refractarios a T-DM1.
MX2018003459A 2015-09-22 2016-09-21 Tratamiento con trastuzumab vc-seco-duba de pacientes de cáncer refractarios a trastuzumab emtansina. MX386402B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15186258 2015-09-22
EP16158710 2016-03-04
EP16169699 2016-05-13
PCT/EP2016/072464 WO2017050846A1 (en) 2015-09-22 2016-09-21 Syd985 treatment of t-dm1 refractory cancer patients

Publications (2)

Publication Number Publication Date
MX2018003459A MX2018003459A (es) 2018-06-06
MX386402B true MX386402B (es) 2025-03-18

Family

ID=57068063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003459A MX386402B (es) 2015-09-22 2016-09-21 Tratamiento con trastuzumab vc-seco-duba de pacientes de cáncer refractarios a trastuzumab emtansina.

Country Status (21)

Country Link
US (1) US10821191B2 (es)
EP (1) EP3352857B1 (es)
JP (1) JP6591665B2 (es)
KR (1) KR20180052761A (es)
CN (1) CN108025190A (es)
AU (1) AU2016328461B2 (es)
BR (1) BR112018005494A2 (es)
CA (1) CA2996600A1 (es)
CL (1) CL2018000726A1 (es)
CY (1) CY1123818T1 (es)
DK (1) DK3352857T3 (es)
ES (1) ES2854298T3 (es)
HR (1) HRP20210418T1 (es)
HU (1) HUE053614T2 (es)
LT (1) LT3352857T (es)
MX (1) MX386402B (es)
MY (1) MY194488A (es)
PL (1) PL3352857T3 (es)
RU (1) RU2728101C2 (es)
WO (1) WO2017050846A1 (es)
ZA (1) ZA201801022B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005484A (es) * 2018-11-09 2021-06-18 Byondis Bv Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados.
KR20220119445A (ko) * 2019-12-20 2022-08-29 화이자 인코포레이티드 부위 특이적 her2 항체-약물 접합체를 사용한 치료
US20240424103A1 (en) * 2021-10-20 2024-12-26 National Institute Of Advanced Industrial Science And Technology Anticancer agent, prodrug of anticancer agent, method for killing cancer cell in vitro, cancer treatement method, and cancer treatment device
PL248499B1 (pl) * 2023-07-28 2025-12-22 Inst Chemii I Techniki Jadrowej Koniugat trastuzumab-emtanzyna znakowany izotopowo o właściwościach przeciwnowotworowych, sposób jego otrzymywania i jego zastosowanie w terapii antynowotworowej

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698541C (en) * 2007-10-19 2018-01-09 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
EP3108886B1 (en) 2010-04-21 2020-06-17 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
JP6342517B2 (ja) * 2014-01-10 2018-06-13 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 改善されたインビボ抗腫瘍活性を示すデュオカルマイシンａｄｃ

Also Published As

Publication number Publication date
EP3352857A1 (en) 2018-08-01
CA2996600A1 (en) 2017-03-30
MX2018003459A (es) 2018-06-06
JP2018527402A (ja) 2018-09-20
LT3352857T (lt) 2021-02-25
US10821191B2 (en) 2020-11-03
CN108025190A (zh) 2018-05-11
CY1123818T1 (el) 2022-05-27
HUE053614T2 (hu) 2021-07-28
DK3352857T3 (da) 2021-03-01
AU2016328461A1 (en) 2018-02-22
CL2018000726A1 (es) 2018-06-01
US20180280533A1 (en) 2018-10-04
RU2018114457A3 (es) 2020-01-31
BR112018005494A2 (pt) 2018-10-09
PL3352857T3 (pl) 2021-08-02
ZA201801022B (en) 2021-05-26
ES2854298T3 (es) 2021-09-21
EP3352857B1 (en) 2021-01-13
KR20180052761A (ko) 2018-05-18
HRP20210418T1 (hr) 2021-04-30
AU2016328461B2 (en) 2021-04-08
RU2018114457A (ru) 2019-10-24
MY194488A (en) 2022-11-30
JP6591665B2 (ja) 2019-10-16
WO2017050846A1 (en) 2017-03-30
RU2728101C2 (ru) 2020-07-28

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2018190719A3 (en) Anti-sirp alpha antibodies
MX2022007522A (es) Anticuerpos anti-cd27.
MD4733B1 (ro) Anticorpi anti-TIGIT
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
GB2541571A (en) Pharmaceutical compositions
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
IN2014MU00303A (es)
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
CY1123818T1 (el) Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
BR112019025164A2 (pt) Esquema de dosagem para tesetaxel e capecitabina
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
MX2017013669A (es) Composiciones para el tramiento del cancer.
MX2023006787A (es) Trastuzumab emtansina para usarse en el tratamiento de cancer de mama residual.